THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN AN INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, ACQUIRE OR DISPOSE OF ANY SHARES OR SECURITIES IN ANY JURISDICTION IN WHICH SUCH INVITATION, SOLICITATION, RECOMMENDATION, OFFER, SUBSCRIPTION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN MAR), AS PERMITTED BY MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. THEREFORE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO THE COMPANY AND ITS SECURITIES.

THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, YOU SHOULD READ AND UNDERSTAND THE INFORMATION PROVIDED IN THE APPENDICES INCLUDING APPENDIX III WHICH CONTAINS THE TERMS AND CONDITIONS OF THE PLACING. THE DEFINITIONS USED IN THIS ANNOUNCEMENT ARE SET OUT IN APPENDIX IV OF THIS ANNOUNCEMENT.

4 November 2024

Feedback plc

("Feedback", or the "Company")

Proposed Placing to raise approximately £5.2 million

Proposed Subscription to raise approximately £70,500

and

Share Capital Reorganisation

Feedback plc, the clinical infrastructure specialist, today announces its intention to raise approximately £5.2 million through a placing ("Placing") of New Ordinary Shares by way of an accelerated bookbuild ("Bookbuild") and a subscription ("Subscription") to raise approximately £70,500 through the issuance of New Ordinary Shares, at an issue price of 20 pence per New Ordinary Share (the "Issue Price"), to new and existing institutional and other investors. The Company also intends to announce a retail offer to qualifying retail investors in the United Kingdom to raise up to a further £1 million (the "Retail Offer", and together with the Placing and Subscription, the "Fundraising").

Net proceeds of the Fundraising will primarily be used to (1) drive growth through the collaboration agreement announced on 19 September 2024 with a large UK primary care partner. The collaboration provides a potential route to rapidly roll out Bleepa, leveraging the existing footprint of the partner to support national engagement. The combined proposition, as a clinical service rather than a technology sale, would provide access to potential large recurrent pots of core funding; (2) provide funding to focus on rolling out Bleepa as a Diagnostic Enhanced Advice and Guidance platform for ICBs under the ERF to optimise the user journey and drive patient referrals from primary care; and (3) net proceeds will also provide on-going working capital for the Group and fund transaction costs.

Certain Directors intend to participate in the Subscription ("Director Participation"). It is intended that the Director Participation will comprise approximately £30,500 in aggregate through the issue of 152,500 New Ordinary Shares at the Issue Price. Further details will be announced as appropriate in due course. The Subscription is conditional on the Placing.

Furthermore, as the Company is not permitted by law to issue Ordinary Shares at an issue price which is below their nominal value, currently 50 pence per Existing Ordinary Share, the Company therefore announces that it is carrying out a share capital reorganisation of its existing issued ordinary share capital to subdivide each Existing Ordinary Share into one New Ordinary Share of one penny and one Deferred Share of 49 pence. The Share Capital Reorganisation (excluding the impact of the Fundraising) will not impact the total number of ordinary shares in issue.

The Issue Price represents a discount of approximately 55 per cent. to the closing mid-market price of 44.5 pence per Existing Ordinary Share on 1 November 2024, being the latest practicable date prior to the publication of this announcement ("Announcement").

RETAIL OFFER

In addition, the Company intends to offer up to 5,000,000 New Ordinary Shares at the Issue Price (the "Retail Offer Shares") through the Winterflood Retail Access platform ("WRAP") to raise up to a further £1 million , to provide qualifying retail investors in the United Kingdom with an opportunity to subscribe for New Ordinary Shares. A further announcement will be made by the Company shortly regarding the Retail Offer and its terms. It is expected that the Retail Offer will launch today, 4 November 2024, shortly after this Announcement and will be open for applications up to 4.30 p.m. on 5 November 2024, or such later time and date as the Company, Panmure Liberum and Winterflood may agree. The result of the Retail Offer is expected to be announced by the Company on or around 6 November 2024. For the avoidance of doubt, the Retail Offer is in addition to the Placing and Subscription. There can be no guarantee that the Retail Offer will be fully subscribed. The Retail Offer is conditional on the Placing.

HIGHLIGHTS

·    Placing to raise gross proceeds of approximately £5.2 million by way of the Bookbuild which will be launched immediately following this Announcement in accordance with the terms and conditions set out in Appendix III of this Announcement.

·    Subscription to raise gross proceeds of approximately £70,500 through the issue of an aggregate of 352,500 New Ordinary Shares at the Issue Price.

·    Retail Offer of New Ordinary Shares to qualifying UK retail investors to raise up to a further £1 million at the Issue Price.

·    Subject to the Fundraising and NHS customers contracting on a timely basis, the Company is targeting EBITDA profitability during 2027.

·    The Fundraising is conditional upon, among other things, the Fundraising Resolutions required to implement the Fundraising being duly passed by Shareholders at the annual general meeting proposed to be held on 28 November 2024 (the "AGM") and Admission.

·    Net proceeds from the Fundraising will primarily be used to:

o  drive growth through product development of Bleepa to expand its functionality for end customers under the collaboration agreement with a primary care partner which provides a potential route to rapidly roll out Bleepa and deliver a neighbourhood diagnostic solution and health record to drive desired changes in the NHS (as described in more detail in Appendix I;

o  provide funding to focus on rolling out Bleepa as a Diagnostic Enhanced Advice and Guidance platform for Integrated Care Boards under the Elective Recovery Fund, including product development to further optimise the user journey and drive patient referrals from primary care; and

o  provide on-going working capital for the Group for at least 12 months following Admission and fund transaction costs.

·    A circular, containing further details of the Fundraising, the Share Capital Reorganisation and the notice of AGM (including the Fundraising Resolutions) (the "Circular"), together with the proxy form, will be posted to Shareholders in due course and will be made available on the Company's website at https://feedbackmedical.com/.

In connection with the Placing, Panmure Liberum is acting as nominated adviser, sole broker and sole bookrunner. The Placing is not being underwritten in any respect and is not being made available to the public. The timing of the closing of the Bookbuild and the allocation of Placing Shares to be issued at the Issue Price is to be determined at the discretion of the Company and Panmure Liberum. A further announcement confirming final details of the Placing will be announced as soon as practicable after the closing of the Bookbuild.

The Fundraising is conditional, inter alia, on the passing of the Fundraising Resolutions by the Shareholders at the Annual General Meeting to be held at 1.00 p.m. on 28 November 2024 at Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT. The Placing is not conditional on the Subscription or Retail Offer, but the Subscription and Retail Offer are each conditional upon completion of the Placing. Should Shareholders not pass the Fundraising Resolutions at the Annual General Meeting, none of the Placing, the Subscription or the Retail Offer will proceed.

Should the Fundraising Resolutions not be passed at the Annual General Meeting and Admission does not occur, the Company will not receive the relevant net proceeds in respect of the Placing, the Subscription or the Retail Offer and the Company may not be able to finance the activities referred to in this Announcement.

Application will be made to the London Stock Exchange for the Placing Shares, the Subscription Shares and such number of Retail Offer Shares as are subscribed for to be admitted to trading on AIM. It is anticipated that, subject to, amongst other things, the approval of the Fundraising Resolutions at the AGM, Admission of the Fundraising Shares to trading on AIM is expected to commence at 8.00 a.m. on 29 November 2024. The Fundraising Shares, when issued, will be fully paid and will (following the Share Capital Reorganisation) rank pari passu in all respects with the rest of the Company's ordinary share capital.

Set out below in Appendix I is an adapted extract from the draft Circular that is proposed to be sent to Shareholders after the closure of the Bookbuild and which provides further information on the Company and the Fundraising.

Capitalised terms used in this Announcement (including the appendices) have the meanings given to them in Appendix IV to this Announcement, unless the context provides otherwise. The expected timetable of the principal events is set out in Appendix II.

Enquiries:

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment, with greater connectivity across organisations.

Our products Bleepa® and CareLocker® work together to deliver unparalleled value to our customers. Bleepa® is our application layer and sits on top of CareLocker® as our data layer. Bleepa® is a clinician facing platform that displays clinical results from a patient's CareLocker® at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker® data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.  

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

IMPORTANT NOTICES

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE TERMS AND CONDITIONS SET OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT") AND THE TERMS AND CONDITIONS SET OUT HEREIN IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN ANY SUCH JURISDICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF SUCH JURISDICTIONS.

This Announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This Announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

This Announcement is not for public release, publication or distribution, in whole or in part, directly or indirectly, in or into Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The securities referred to herein have not been and will not be registered under the securities laws of Australia, Canada, the Republic of South Africa, Japan or any state, province or territory thereof or any other jurisdiction outside the United Kingdom, except pursuant to an applicable exemption from the registration requirements and in compliance with any applicable securities laws of any state, province or other jurisdiction of Australia, Canada, the Republic of South Africa or Japan (as the case may be).

No public offering of the Placing Shares is being made in Australia, Canada, the Republic of South Africa, Japan or elsewhere.

No action has been taken by the Company or Panmure Liberum, their affiliates, or any of their respective directors, officers, partners, employees, advisers, consultants and/or agents (collectively, "Representatives") that would permit an offer of the Placing Shares or possession or distribution of this Announcement or any other publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required. Persons receiving this Announcement are required to inform themselves about and to observe any restrictions contained in this Announcement. Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this Announcement should seek appropriate advice before taking any action. Persons distributing any part of this Announcement must satisfy themselves that it is lawful to do so.

No offering document or prospectus will be made available in any jurisdiction in connection with the matters contained or referred to in this Announcement or the Placing and no such prospectus is required to be published.

Certain statements in this Announcement are forward-looking statements with respect to the Company's expectations, intentions and projections regarding its future performance, strategic initiatives, anticipated events or trends and other matters that are not historical facts and which are, by their nature, inherently predictive, speculative and involve risks and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. All statements that address expectations or projections about the future, including statements about operating performance, strategic initiatives, objectives, market position, industry trends, general economic conditions, expected expenditures, expected cost savings and financial results, are forward-looking statements. Any statements contained in this Announcement that are not statements of historical fact are, or may be deemed to be, forward‐looking statements. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "could", "intend", "estimate", "expect", "may", "plan", "project" or words or terms of similar meaning or the negative thereof, are not guarantees of future performance and are subject to known and unknown risks and uncertainties. There are a number of factors including, but not limited to, commercial, operational, economic and financial factors, that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied by these forward‐looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as changes in taxation or fiscal policy, future market conditions, currency fluctuations, the behaviour of other market participants, the actions of governments or governmental regulators, or other risk factors, such as changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including inflation, recession and consumer confidence, on a global, regional or national basis. Given those risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this Announcement. Each of the Company and Panmure Liberum expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by applicable law or regulation.

Panmure Liberum, which is authorised and regulated in the United Kingdom by the FCA, is acting as nominated adviser and sole bookrunner to the Company in connection with the Placing and Admission and to no-one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in relation to the Placing or Admission or any other matter referred to in this Announcement. Panmure Liberum's responsibilities as the Company's nominated adviser under the AIM Rules for Nominated Advisers are owed solely to London Stock Exchange plc and are not owed to the Company or to any director of the Company or to any other person in respect of any decision to acquire shares in the Company in reliance on any part of this Announcement.

Neither Panmure Liberum or its affiliates, nor any of their respective Representatives, accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to this Announcement, including the truth, accuracy or completeness of the information in this Announcement (or whether any information has been omitted from the Announcement) or for any loss howsoever arising from any use of the Announcement or its contents. Panmure Liberum, their affiliates and their Representatives, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise have in respect of this Announcement or its contents or otherwise arising in connection therewith.

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this Announcement.

This Announcement has been prepared for the purposes of complying with applicable law and regulation in the United Kingdom and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside the United Kingdom.

No statement in this Announcement is intended to be a profit forecast or estimate, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

The New Ordinary Shares to be issued pursuant to the Fundraising will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange.

INFORMATION TO DISTRIBUTORS

UK product governance

Solely for the purposes of the product governance requirements contained within of Chapter 3 of the FCA Handbook Production Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of investors who meet the criteria of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in paragraph 3 of the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all distribution channels (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors (for the purposes of UK Product Governance Requirements) should note that: (a) the price of the Placing Shares may decline and investors could lose all or part of their investment; (b) the Placing Shares offer no guaranteed income and no capital protection; and (c) an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Panmure Liberum will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapter 9A or 10A respectively of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

EEA product governance

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures in the European Economic Area (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Panmure Liberum will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

APPENDIX I

1.    BACKGROUND TO AND REASONS FOR THE FUNDRAISING

a)    Introduction

Feedback liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. It connects care settings with diagnostic and other relevant data to drive better, faster, safer decisions that improve outcomes for patients.

By linking different clinical systems together into a seamless view of the patient, it can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

Feedback is focused on commercialising its range of proprietary products:

·    Bleepa, a communication and collaboration platform that displays clinical results at a certified and regulated quality, enabling multi-disciplinary team working and diagnostic-enhanced advice and guidance. It enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record;

·    CareLocker, a patient-facing platform that gives patients access and control over their diagnostic and other clinical data; and

·    Feedback Connect (formerly Bleepa Box), a specialist tool to enable image transfer from remote settings to the Bleepa platform.

The Company's products incorporate a diagnostic medical image display that conforms with the required standards stipulated for clinical use, as certified by the UKCA mark. Under the prevailing legislation it is a legal requirement that products used to display digital patient images (such as photos, X-rays, CT scans and MRIs) for a diagnostic purpose are appropriately certified as medical devices. The Directors believe that Bleepa is currently the only commercial clinical communication platform to be certified as a medical device that is capable of displaying digital patient images at a quality suitable for clinical review.

The Company's technologies are currently in use in a number of UK NHS Trusts. The Directors believe that there are very significant commercialisation and expansion opportunities both within these existing markets and also in other healthcare settings. The Directors believe there is an estimated total addressable market for Bleepa (including Feedback Connect) and CareLocker in core target markets of approximately £10 billion.

Unlike generic communication platforms, Feedback's technology is patient-centric; designed to facilitate communication around a specific patient's clinical pathway and allowing centralisation of information. The Company's products are designed to be compliant with information governance and clinical safety standards, whilst also mirroring how clinical care is delivered - to individual patients. The patient-centric technology architecture also enables Feedback's products to link to other clinical systems and enables integration of user generated content into an individual patient's medical record.

The Directors believe the Company's products could be an essential element to facilitate the digital transformation of healthcare, a key priority for the NHS as outlined by recent statement from Wes Streeting (Secretary of State for Health and Social Care) in addition to the "Independent Investigation of NHS in England" published by Lord Darzi, the Tony Blair Institute and the All-Party Parliamentary Group for Diagnostics report, as outlined below.

The Directors believe the recent collaboration agreement with a large UK primary care record provider, as announced on 19 September 2024, will provide a potential route to rapidly roll out Bleepa and assist the NHS to develop a nationwide Neighbourhood Diagnostic Solution utilising the partner's existing infrastructure and Feedback's scalable technology pathway. The Company anticipates commencing a pilot study with its partner for the Neighbourhood Diagnostic Solution with an NHS Trust in the fourth quarter of 2024. Additionally, the Directors believe that the recent confirmation that the Diagnostic Enhanced Advice and Guidance diversions achieved through the Bleepa platform are eligible for reimbursement under the ERF provides a credible route to scale through contracting opportunities.

b)    Product Portfolio

Bleepa:

Bleepa is a unique clinical communication platform in the UK using asynchronous communication channels built around individual patient pathways which allows medical staff to securely view and discuss high quality medical grade images across both mobile and desktop devices as well as manage patient pathways and workflow. The platform allows clinicians to review patient imaging and reports with access to picture archiving and communication systems ("PACS") and discuss cases collaboratively with colleagues on the go through the integrated messenger application.

Bleepa operates a SaaS model of recurring revenues. Prices vary between NHS and private sector offerings but typically follow a fixed price per user per year (subject to a minimum number of users) or a price per patient episode (subject to a minimum number of patient episodes), both on a recurring annual contract basis.

The Company licences Bleepa directly to customers, providing cloud hosting unless the customer wishes to host the service directly (on-premises), in which case the Company installs the system locally at the customer site. Feedback provides direct deployment and integration support to facilitate a smooth set up of the product and supports the customer with user training and onboarding where required (customers typically deliver this themselves using Feedback's standard training and user manuals as part of their business as usual processes). Feedback's product support team provides ongoing customer support for the duration of the product licence, which typically does not include user management such as login requests which are managed locally by the customer.

Key features of Bleepa:

·    Creates a common view of a patient's data, securely accessible from any location with an internet connection.

·    Provides an asynchronous collaboration environment that allows clinicians to contribute to cases in and around other clinical work, at a time that is convenient for them.

·    Bridges the gap between care settings enabling seamless clinical pathway delivery between primary care, secondary care and the community.

·    The Directors believe Bleepa is the only communication and workflow tool to be certified as a medical device for clinical image display.

·    Dashboard view gives oversight of any patient on any Bleepa care pathway.

What this means for care:

·    Clinicians can review and discuss cases at any time, from any place with an internet connection; giving greater flexibility and boosting capacity to manage growing caseloads.

·    Patients can be reviewed outside of traditional clinical and meeting structures, allowing decisions to be made more rapidly, accelerating their journey.

·    Providers are able to run coordinated patient pathways between any care setting with fewer clinicians, whilst ensuring clinical oversight and appropriate use of diagnostic resources.

·    Providers can see where all their patients are in a care pathway, at any time and across all care settings. Auditable capture of all clinical discussions.

·    Providers can conform with the CQC requirement for a single contemporaneous record, as well as complying with GDPR/MDD regulatory requirements.

·    Providers can avoid GDPR data breach fines from the Information Commissioner's Office for using WhatsApp.

Key benefits are:

·    Saves time:

o  63% reduction in patient wait times compared to national 18-week referral to treatment target.[1]

o  45% reduction in patient wait times from referral to diagnostic test, compared to the national target. ¹

o  87% reduction in clinical response time.[2]

o  74% reduction in time from submission of a referral to first review.²

·    Reduces costs¹:

o  Estimated 88% reduction in outpatient appointment requirement which could save an estimated £295 per patient episode.

o  Reduction in staff requirements and associated costs - ability to manage a regional / national caseload with a smaller pool of specialists in a timely way.

o  Reduction in carbon footprint - deliver greener services with the Company's cloud architecture.

CareLocker:

CareLocker is a patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

Key features of CareLocker:

·    Provides secure, easy-to-use management of patient's imaging from the convenience of their own mobile.

·    Can be 'white labelled' with the branding of the purchaser, or it can be integrated within other health and lifestyle apps for a seamless user experience.

·    Patient centric cloud architecture that bridges care settings and follows the patient across provider sites with better scalability, security and auditability.

Key benefits are:

·    Common view: brings data from different care settings into one place.

·    Secure storage: patient data can be stored in individual 'lockers' meaning it is more secure, limiting the risks of cyber security incidents.

·    Patient empowerment: patients can access and add data related to their ongoing care from their own device.

·    Clinician access: patients can invite clinicians to view their healthcare information in the app.

Feedback Connect:

Feedback Connect (formerly BleepaBox) enables imaging-led, point-of-care decision making in previously unreachable or disconnected areas, such as community or rural locations, where remote analysis is needed. It enables smoother transfer of images and other data over a mobile network from anywhere, speeding up access to the information for clinicians and faster treatment decisions for patients.

Key features of Feedback Connect:

·      Matches medical images and other data directly to patients.

·      Transfers DICOM studies and medical images with a secure, encrypted connection.

·      A virtual private network (VPN) connection is not required.

·      Shares images with a 3G/4G/5G wireless connection.

·      Takes jpg images and creates DICOM compatible files to add to PACS.

c)    Market Opportunities

Healthcare is a complex market globally, with multiple stakeholders both within and across multiple discrete provider settings, each with different procurement and funding processes. The Company's key market is the UK, particularly the NHS, which can be divided into the following customer groups:

The new UK government, elected in July 2024, is seeking to deliver a renewed focus and increased momentum towards transforming the NHS, a key objective being to deliver a reduction in waiting lists. The recent publication of the "Independent Investigation of the NHS in England" by Lord Darzi highlights a need for rapid change. Of the seven themes of how to repair the NHS, three could be addressed by building a more integrated technological platform: the delivery of a "neighbourhood NHS", the "tilt towards technology" and "driving productivity in hospitals". These themes, in particular the use of technology, were also drawn out in the August 2024 report by the Tony Blair Institute for Global Change "Preparing the NHS for the AI Era:" (the "Tony Blair Institute Report").

Wes Streeting, the new Secretary of State for Health and Social Care, has called for a "Neighbourhood Health Service" stating his belief that the NHS must move its focus "from hospital to community", "analogue to digital" and "sickness to prevention". Additionally, the Tony Blair Institute Report also laid out the case for a single care record and recommends that this is built out from the current primary care record. Feedback now has an MVP with a prif3mary record partner to be able to deliver a neighbourhood diagnostic solution and health record which could help to drive the desired changes in the NHS.

The Directors believe Feedback is well placed to address some of the challenges facing the NHS, providing a scalable platform to transform patient care pathways and the way in which clinicians communicate. As illustrated through the data generated as part of its pilot studies with the Queen Victoria Hospital NHS Foundation Trust, Feedback has demonstrated the potential significant costs benefits to the NHS and ultimately driving a reduction in waitlists through more efficient referrals, reduced amount of time required by staff and shorter lengths of stay for patients. Bleepa was featured in the All-Party Parliamentary Group for Diagnostics report in January 2024 as a key programme delivering impact under the Community Diagnostics Programme, which opened national team dialogue.

Collaboration agreement with a provider of primary care solutions

On 19 September 2024, the Company announced it had signed a collaboration agreement with a provider of primary care solutions to explore the opportunities for a novel "Neighbourhood Diagnostics Solution" that combines the partner's technology and Bleepa aiming to streamline NHS diagnostic and pathway referrals between primary care, CDCs and secondary care. The solution is expected to enable some diagnostic procedures to be referred into community settings such as pharmacy or other diagnostic facilities, enhancing diagnostic capacity to support NHS waitlist recovery.

The parties intend to pilot the solution, before pursuing broader national opportunities if the pilot proves successful, to demonstrate an expected reduction in outpatient appointment requirement through the combined platform, further reduction in patient wait times through an optimised GP referral process and also the ability to scale the solution at pace to multiple GP practices simultaneously. The Company anticipates that it will enter into a memorandum of understanding with its partner and an NHS trust to pilot the Neighbourhood Diagnostic Solution during the fourth quarter of 2024.

The collaboration provides a potential route to rapidly scale the Bleepa solution and pathway approach, following a successful pilot, leveraging the existing footprint of the partner who also brings a strong balance sheet and large workforce to support national engagement. The combined proposition, as a clinical service rather than a technology sale, would provide access to potential large recurrent pots of core funding. The technology is a component of the clinical services contract. This increases the length of potential contracts and lifetime value

The Company estimates that over 190 million diagnostic investigations per year could be redirected to a pharmacy setting. If taken to a national scale, this opportunity could represent an estimated TAM of £382 million annually (of which Feedback's share of the TAM is estimated as £191 million per annum[3]) with further opportunities for potential international expansion. Commercial revenue from this potential opportunity remains subject to, inter alia, successful pilots and commercial agreement between the parties.

Bleepa as a DEAG tool supported by the ERF

On 16 October 2024, the Company announced that the Diagnostic Enhanced Advice and Guidance diversions achieved through the Bleepa platform are now eligible for reimbursement under the ERF. This funding mechanism allows any ICB or hospital in England to immediately utilise this funding to reimburse expenditure on the Bleepa technology. The ERF is a revenue-based payment mechanism designed to incentivise NHS organisations to reduce waitlists.

The ERF reimbursement model offers a single payment of £206 per diversion from traditional outpatient appointments through the DEAG pathway facilitated by Bleepa. There are no limitations on the number of patients or pathways that are eligible under the funding mechanism, the more activity delivered and diversions achieved the more an ICB will be reimbursed. Based on existing programmes at Queen Victoria Hospital NHS Foundation Trust, the Company estimates up to 90 per cent. of referrals could be diverted using the DEAG approach, resulting in material efficiencies and patient benefits, including an estimated 63 per cent. reduction in wait times.

To rapidly scale this solution, the Company has formed a strategic partnership with Moorhouse Consulting ("Moorhouse") as its implementation partner. Feedback has already undertaken a roadshow of NHS ICBs, generating interest in the Bleepa DEAG approach. With ERF reimbursement, the Company anticipates converting a number of these ICBs into customer contracts. Based on expected patient volumes once fully rolled out, the Company believes that an indicative contract could generate over approximately £2 million per annum for Feedback under the ERF mechanism per ICB (assuming 66,000 patients per annum and that ERF rolls forward on an un-capped basis annually). Unlocking ERF is expected to significantly improve customer access to Bleepa as it aligns with service-based reimbursement, potentially providing greater funding security and recurring revenue opportunities for the Company. ERF currently runs until 31 March 2025, but the Company believes, following central NHS conversations, that the funding may be renewed in subsequent financial years to continue to support waitlist reduction.

Opportunities outside the NHS

The Company's technologies address clinical pain points that are felt around the world, namely growing wait lists, staff shortages and spiralling costs. In combination Bleepa and CareLocker help the Company's customers do more with less, ultimately accelerating patient care through the power of collaboration and good quality access to data in a way that increases the flexibility of staff location and availability.

Although the UK is the Company's domestic market and main focus, the Company is pursuing opportunities for its technologies in India and there are further markets, such as the USA, that could hold significant possibilities for growth through replication of the value-based care models that the Company's technologies have enabled in the UK.

The Company's primary focus is currently within the UK and securing contracts with the NHS as described above. As such the Company does not plan to incur significant costs in relation to international expansion above the de minimis recurring costs until such time as the Company is generating meaningful revenue from UK contracts or has access to additional funding.

Figure 1: Taken together across its core markets, Feedback estimate the total addressable market to be approximately £10 billion.

d)    Reasons for the Fundraising

As outlined above, the Directors believe that Feedback has multiple opportunities for revenue growth and value creation for Shareholders across its products and is strategically well placed to capitalise on the renewed political focus to transform the NHS. In order to deliver the growth opportunities, the Group is intending to raise approximately £5.2 million through the Placing and £70,500 through the Subscription in order to provide a sound financial platform allowing Feedback to develop its products, deliver pilots and increase sales opportunities.

e)    Financial results

The Company has also announced today its audited results for the year ended 31 May 2024. A copy of the annual report is available on the Company's website at https://feedbackmedical.com/resources/resource-hub/.

2.    USE OF PROCEEDS

It is intended that the net proceeds of the Fundraising will principally be used to:

1.    drive growth through product development of Bleepa to expand its functionality for end customers under the collaboration agreement with a primary care partner which provides a potential route to rapidly roll out Bleepa and deliver a neighbourhood diagnostic solution and health record to drive the desired changes in the NHS as described above;

2.    provide funding to focus on rolling out Bleepa as a Diagnostic Enhanced Advice and Guidance platform for ICBs under the ERF, including product development to further optimise the user journey and drive patient referrals from primary care; and

3.    provide on-going working capital for the Group for at least 12 months following Admission and fund transaction costs.

It is intended that the net proceeds of the Retail Offer will be used to provide general working capital and balance sheet strength.

Funding is intended to deliver scale-up and balance sheet strength, targeting EBITDA profitability in 2027, albeit dependant on NHS customers contracting on a timely basis.

3.    BACKGROUND TO AND REASONS FOR THE SHARE CAPITAL REORGANISATION

Under the Act, a company is unable to issue shares at a subscription price which is less than the nominal value of shares of the same class. This means that, as the nominal value of the Existing Ordinary Shares is currently 50 pence, the Company could not issue further Existing Ordinary Shares at the Issue Price without a sub-division of the Existing Ordinary Shares. The Board, therefore, has concluded that it is essential to implement the Share Capital Reorganisation in order for the nominal value of the New Ordinary Shares to become lower than the Issue Price, so that the Company can proceed with the Fundraising. The Share Capital Reorganisation is conditional upon completion of the Fundraising.

Accordingly, it is proposed to sub-divide each Existing Ordinary Share into one New Ordinary Share of one penny (one penny being the proposed new nominal value per share) and one Deferred Share of 49 pence.

The New Ordinary Shares will, in all material respects, have the same rights (including rights as to voting, dividends and return of capital) as the Existing Ordinary Shares, save for their nominal value. The New Ordinary Shares will be traded on AIM in the same way as the Existing Ordinary Shares, with the exception of the difference in nominal value. The nominal value of shares already held in CREST will be updated at approximately 8.00 a.m. on 29 November 2024.

The rights attached to the Deferred Shares will be set out in the Articles (as per Resolution 2 in the Notice of Annual General Meeting). The Deferred Shares will have little or no economic value as they will not carry any rights to vote or dividend rights, nor (realistically) have any entitlement to a share of assets on a return of capital or on a winding up of the Company. The Company does not intend to make any application for the Deferred Shares to be admitted to trading on AIM or any other public market. The Deferred Shares will not be transferable without the prior written consent of the Company. No share certificates will be issued in respect of the Deferred Shares. The Board may further appoint any person to act on behalf of all the holders of the Deferred Shares to transfer all such shares to the Company in accordance with the terms of the Act.

The Company does not intend to issue new share certificates to the holders of the New Ordinary Shares following the Share Capital Reorganisation. Existing share certificates will remain valid for the same number of shares but with a different nominal value of one penny per New Ordinary Share. Following the Share Capital Reorganisation should you wish to receive an updated share certificate please contact the Registrars at the address set out in this document.

Holders of options over Existing Ordinary Shares will maintain the same rights as currently accruing to them and will not be issued with new option certificates.

By effecting the Share Capital Reorganisation, the total nominal value of the issued share capital of the Company will remain the same, with New Ordinary Shares having a nominal value of one penny each plus Deferred Shares having a nominal value of 49 pence each. The Share Capital Reorganisation is conditional upon, and effected by, the approval of Resolutions 1 and 2 at the Annual General Meeting as required by the Act and the Articles. If Resolutions 1 to 4 are passed, the Share Capital Reorganisation will become effective at approximately 8.00 a.m. on 29 November 2024.

Please note that the Fundraising cannot take place unless the Share Capital Reorganisation is approved. Accordingly, if the Share Capital Reorganisation Resolutions are not approved by Shareholders at the Annual General Meeting, the Fundraising will not proceed, and the Company will not be able to receive the new funds from investors in order to develop its business in the manner otherwise contemplated in this announcement.

4.    DETAILS OF THE FUNDRAISING

The Company is proposing to raise approximately £5.2 million (before expenses) through a Placing and £70,500 through a Subscription to new and existing institutional and other investors at the Issue Price. In addition to the Placing and Subscription, the Company intends to launch a Retail Offer to raise up to a further £1 million (before expenses) pursuant to which qualifying retail investors in the UK will have the opportunity to subscribe for New Ordinary Shares at the Issue Price.

Certain Directors of the Company intend to participate in the Subscription. It is intended that the Director Participation will comprise approximately £30,500 in aggregate through the issue of 152,500 New Ordinary Shares at the Issue Price. Further details will be announced as appropriate in due course. 

The Fundraising is not being underwritten and is conditional, inter alia, upon:

a)     the passing of the Fundraising Resolutions;

b)    the Placing Agreement becoming unconditional in all respects (other than Admission) and not having been terminated in accordance with its terms; and

c)     Admission occurring by no later than 8.00 a.m. on 29 November 2024 (or such later time and/or date as the Company, Panmure Liberum may agree, not being later than 31 December 2024).

The Placing is not conditional upon the completion of the Subscription or the Retail Offer but is conditional upon the Share Capital Reorganisation. Completion of the Subscription and the Retail Offer are conditional, inter alia, upon completion of the Share Capital Reorganisation and the Placing.

Accordingly, if any of the conditions are not satisfied or waived (where capable of waiver), the Fundraising will not proceed, the Fundraising Shares will not be issued and all monies received by Panmure Liberum, the WRAP Platform or the Company (as the case may be) will be returned to the applicants (at the applicants' risk and without interest) as soon as possible thereafter. 

The Directors believe that the New Ordinary Shares to be issued pursuant to the Placing, Subscription and Retail Offer will rank as 'eligible shares' for the purposes of EIS and will be capable of being a "qualifying holding" for the purposes of investment by VCTs. Further details as regards EIS and VCT reliefs are set out in the Circular.  

Details of the Placing

Under the terms of the Placing Agreement, Panmure Liberum has agreed to use its reasonable endeavours to procure subscribers for the Placing Shares at the Issue Price. The Placing Agreement contains certain customary warranties and indemnities from the Company in favour of Panmure Liberum. Panmure Liberum may terminate the Placing Agreement in certain circumstances. The Placing is not underwritten and is conditional on the Share Capital Reorganisation and Admission. The terms and conditions of the Placing are set out in Appendix III of this Announcement.

Subscription

Certain Directors of the Company and certain other existing Shareholders intend to subscribe for in aggregate 352,500 Subscription Shares at the Issue Price to raise gross proceeds of approximately £70,500. The Subscription is not underwritten and is conditional on the Share Capital Reorganisation, Admission and completion of the Placing.

If the conditions for the Subscription are not satisfied or waived (where capable of waiver), the Subscription will lapse and the Subscription Shares will not be allotted and issued and no monies will be received by the Company pursuant to the Subscription.

The Subscription Shares will, when issued and fully paid, rank pari passu in all respects with the other New Ordinary Shares then in issue, including the right to receive all dividends and other distributions declared, made or paid after the date of Admission.

5.    EIS AND VCT

On issue, the Fundraising Shares will not be treated as either "listed" or "quoted" securities for the purposes of the enterprise investment scheme (EIS) or the venture capital trust (VCT) regime. Provided that the Company remains one which does not have any of its shares quoted on a recognised stock exchange (which for these purposes does not include AIM), the Fundraising Shares should continue to be treated as unquoted securities in the same way as the Existing Ordinary Shares.

The Board believes that the Fundraising Shares will rank as 'eligible shares' for the purposes of EIS and will be capable of being a 'qualifying holding' for the purposes of investment by VCTs.

The Company has received EIS advance assurance from HMRC.

As the rules governing EIS and VCT reliefs are complex and interrelated with other legislation, if Shareholders and potential shareholders are in any doubt as to their tax position, require more detailed information than the general outline above, or are subject to tax in a jurisdiction other than the United Kingdom, they should consult their own independent professional financial adviser.  

5.     DIRECTORS' RECOMMENDATION

The Directors consider the Fundraising to be in the best interests of the Company and Shareholders as a whole. The Directors also consider the passing of the Resolutions (including the Fundraising Resolutions) to be in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend unanimously that Shareholders vote in favour of the Resolutions (including the Fundraising Resolutions) to be proposed at the Annual General Meeting, as they intend to do in respect of their own shareholdings, which total 118,148 Existing Ordinary Shares (representing approximately 0.89 per cent. of the Existing Ordinary Shares).

APPENDIX II

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

If any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service. 

Certain of the events in the above timetable are conditional upon, inter alia, the approval of the Fundraising Resolutions to be proposed at the Annual General Meeting.

All references to time and dates in this Announcement are to time and dates in London.

APPENDIX III

TERMS AND CONDITIONS OF THE PLACING

INTRODUCTION

IMPORTANT INFORMATION FOR INVITED PLACEES ONLY REGARDING THE PLACING.

MEMBERS OF THE PUBLIC IN THE UK OR ELSEWHERE ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT (INCLUDING THIS APPENDIX) AND THE TERMS AND CONDITIONS SET OUT HEREIN ARE FOR INFORMATION PURPOSES ONLY AND ARE DIRECTED ONLY AT: (A) PERSONS IN AN EU MEMBER STATE WHO ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 2(E) OF THE EU PROSPECTUS REGULATION ("EU QUALIFIED INVESTORS"); OR (B) PERSONS IN THE UNITED KINGDOM WHO ARE QUALIFIED INVESTORS ("UK QUALIFIED INVESTORS") WITHIN THE MEANING OF ARTICLE 2(E) OF THE UK PROSPECTUS REGULATION AS IT FORMS PART OF DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK PROSPECTUS REGULATION")WHO ALSO (I) FALL WITHIN THE DEFINITION OF 'INVESTMENT PROFESSIONAL' IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 ("FINANCIAL PROMOTION ORDER"), OR (II) FALL WITHIN ARTICLE 49(2)(A) TO (D) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC) OF THE FINANCIAL PROMOTION ORDER; OR (C) OTHER PERSONS TO WHOM IT MAY LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS ANNOUNCEMENT (INCLUDING THIS APPENDIX) AND THE TERMS AND CONDITIONS SET OUT HEREIN MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT (INCLUDING THIS APPENDIX) AND THE TERMS AND CONDITIONS SET OUT HEREIN RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THIS ANNOUNCEMENT, INCLUDING THIS APPENDIX, AND THE INFORMATION IN IT, IS RESTRICTED, AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART TO U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933 (AS AMENDED) ("SECURITIES ACT") OR, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR NEW ZEALAND ("RESTRICTED JURISDICTIONS") OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT, INCLUDING THIS APPENDIX, IS NOT AN OFFER FOR SALE OR SUBSCRIPTION IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. THIS ANNOUNCEMENT, INCLUDING THIS APPENDIX, IS NOT AN OFFER OF OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES. NO PUBLIC OFFERING IS BEING MADE IN THE UNITED STATES.

EACH PLACEE SHOULD CONSULT WITH ITS OWN ADVISERS AS TO LEGAL, TAX, BUSINESS, ACCOUNTING AND RELATED ASPECTS OF AN INVESTMENT IN THE PLACING SHARES. THE PRICE OF THE PLACING SHARES IN THE COMPANY AND THE INCOME FROM THEM (IF ANY) MAY GO DOWN AS WELL AS UP AND INVESTORS MAY NOT GET BACK THE FULL AMOUNT INVESTED ON DISPOSAL OF THE PLACING SHARES.

Placees will be deemed to have read and understood this announcement and these terms and conditions in their entirety and to be making any offer to participate in the Placing on these terms and conditions and to be providing the representations, warranties, acknowledgements, and undertakings contained in this Appendix. In particular, each such Placee represents, warrants and acknowledges that:

1. it is a Relevant Person and undertakes that it will acquire, hold, manage or dispose of any Placing Shares that are allocated to it for the purposes of its business

2. in the case of any Placing Shares acquired by it as a financial intermediary, as that term is used in Article 5(1) of the UK Prospectus Regulation, (i) the Placing Shares acquired by it have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State of the EEA or the UK other than EU Qualified Investors under Article 2(e) the EU Prospectus Regulation, or UK Qualified Investors or in circumstances in which the prior consent of Panmure Liberum has been given to the offer or resale; or (ii) where Placing Shares have been acquired by it on behalf of persons in any Member State of the EEA or the UK other than EU Qualified Investors or UK Qualified Investors, the offer of those Placing Shares to it is not treated under the Prospectus Regulation as having been made to such persons; and/or

3. (1) it is not a U.S. Person, (2) it is not located in the United States, and (3) it is not acquiring the Placing Shares for the account or benefit of a U.S. Person.

The Company and Panmure Liberum will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. Panmure Liberum does not make any representation to any Placee regarding an investment in the Placing Shares referred to in this Announcement (including this Appendix).

This Announcement (including this Appendix) does not constitute an offer and may not be used in connection with an offer, to sell or issue or the solicitation of an offer to buy or subscribe for Placing Shares in any jurisdiction in which such offer or solicitation is or may be unlawful. This Announcement (including this Appendix) and the information contained herein is not for publication or distribution, directly or indirectly, to persons in the United States, the Restricted Jurisdictions or in any jurisdiction in which such publication or distribution is unlawful. Persons who come into possession of this Announcement are required by the Company to inform themselves about and to observe any restrictions of transfer of this Announcement. No public offer of securities of the Company under the Placing is being made in the United Kingdom, the United States or any Restricted Jurisdiction.

In particular, the Placing Shares referred to in this announcement have not been and will not be registered under the Securities Act or under any laws of, or with any securities regulatory authority of, any state or other jurisdiction of the United States, and may not be offered, sold, resold, transferred or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, U.S. Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction in the United States, and under circumstances that would not result in the Company being in violation of the U.S. Investment Company Act. The Placing Shares are only being offered and sold outside the United States in offshore transactions to persons who are not U.S. Persons in accordance with Regulation S under the Securities Act or within the United States to a limited number of investors reasonably believed to be "qualified institutional buyers" ("QIBS") as defined in rule 144a under the US Securities Act pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada; no prospectus has been lodged with or registered by the Australian Securities and Investments Commission or the Japanese Ministry of Finance; and the Placing Shares have not been, nor will they be, registered under or offered in compliance with the securities laws of any state, province or territory of any of the Restricted Jurisdiction. Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into the Restricted Jurisdiction or any other jurisdiction outside the United Kingdom.

Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this Appendix or the announcement of which it forms part should seek appropriate advice before taking any action. Persons into whose possession this Appendix or the announcement comes are required by each of the Company and Panmure Liberum to inform themselves about, and to observe, any such restrictions.

DETAILS OF THE PLACING AGREEMENT

Panmure Liberum has entered into the Placing Agreement with the Company under which Panmure Liberum has, on the terms and subject to the conditions set out therein, undertaken to use its reasonable endeavours to procure, as agent for the Company, subscribers for the Placing Shares at the Issue Price. The Placing is not being underwritten by Panmure Liberum or any other person nor is any part of the Placing subject to clawback from the Retail Offer or conditional on the Retail Offer or the Subscription.

The Placing Agreement contains customary warranties given by the Company to Panmure Liberum as to matters relating to the Company and its business and a customary indemnity given by the Company to Panmure Liberum in respect of liabilities arising out of, or in connection with, the Placing.

Panmure Liberum (after consultation with the Company) reserves the right to scale back the number of Placing Shares to be subscribed by any Placee in the event of applications in excess of the target amount under the Placing. The Company and Panmure Liberum also reserve the right not to accept offers to subscribe for Placing Shares or to accept such offer in part rather than in whole. Panmure Liberum shall be entitled to effect the Placing by such method as it shall in its sole discretion determine. To the fullest extent permissible by law, neither Panmure Liberum nor any holding company of Panmure Liberum nor any subsidiary branch or affiliate of Panmure Liberum (each an affiliate) nor any person acting on behalf of any of the foregoing shall have any liability to the Placees (or to any other person whether acting on behalf of a Placee or otherwise). In particular, neither Panmure Liberum, nor any affiliate thereof nor any person acting on their behalf shall have any liability to Placees in respect of their conduct of the Bookbuild or the Placing.

Each Placee's obligations will be owed to the Company and to Panmure Liberum. Following the confirmation referred to below in the paragraph entitled "Participation in, and principal terms of, the Placing", each Placee will also have an immediate, separate, irrevocable and binding obligation, owed to Panmure Liberum, to pay to Panmure Liberum (or as Panmure Liberum may direct) in cleared funds an amount equal to the product of the Issue Price and the number of Placing Shares which such Placees has agreed to acquire.

Each Placee and any person acting on behalf of such Placee agrees to indemnify on demand and hold each of Panmure Liberum and the Company, and their respective affiliates harmless from any costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the acknowledgments, undertakings, representations, warranties and agreements set forth in these terms and conditions and any contract note.

The Placing is also conditional upon the Placing Agreement becoming unconditional and not being terminated in accordance with its terms. Further details of conditions in relation to the Placing are set out below in the paragraph entitled "Conditions of the Placing".

To the fullest extent permitted by law, each Placee acknowledges and agrees that it will not be entitled to exercise any remedy of rescission at any time. This does not affect any other rights the Placee may have.

APPLICATION FOR ADMISSION TO TRADING

Application will be made to the London Stock Exchange for Admission. It is expected that settlement of the Placing Shares and Admission will become effective on or around 8.00 a.m. on 29 November 2024 and that dealings in the Placing Shares will commence at that time.

PAYMENT FOR SHARES

Each Placee has a separate, irrevocable and binding obligation to pay the Issue Price in cleared funds for the number of Placing Shares duly allocated to the Placee under the Placing in the manner and by the time directed by Panmure Liberum. If any Placee fails to pay as so directed and/or by the time directed, the relevant Placee's application for Placing Shares shall at Panmure Liberum's discretion either be rejected or accepted in which case the paragraph below entitled "Registration and Settlement" shall apply to such application.

PARTICIPATION IN, AND PRINCIPAL TERMS OF, THE PLACING

Panmure Liberum (whether through itself or any of its affiliates) is arranging the Placing as placing agent of the Company and using its reasonable endeavours to procure Placees at the Issue Price for the Placing Shares.

Participation in the Placing will only be available to persons who may lawfully be, and are, invited to participate by Panmure Liberum. Panmure Liberum and its affiliates may participate in the Placing as principal.

By participating in the Placing, Placees will be deemed to have read and understood this Announcement, including this Appendix, in its entirety and to be participating and making an offer for Placing Shares on the terms and conditions, and to be providing the representations, warranties, acknowledgements, agreements and undertakings contained in this Appendix.

This Appendix gives details of the terms and conditions of, and the mechanics of participation in, the Placing. No commissions will be paid to Placees or by Placees in respect of any Placing Shares.

The number of Placing Shares to be issued, and the extent of each Placee's participation in the Placing (which will not necessarily be the same for each Placee), will be agreed by Panmure Liberum, (following consultation with the Company) following completion of the bookbuilding process in respect of the Placing (the "Bookbuild"). No element of the Placing will be underwritten. The aggregate number of Placing Shares will be announced on a Regulatory Information Service following completion of the Bookbuild.

A Placee's commitment to acquire a fixed number of Placing Shares under the Placing will be agreed orally or by email with Panmure Liberum as agent of the Company. Each Placee's allocation will be confirmed to Placees orally or by email by Panmure Liberum, and a contract note will be dispatched as soon as possible thereafter. The oral or email confirmation to such Placee will constitute an irrevocable legally binding commitment upon such person (who will at that point become a Placee) in favour of Panmure Liberum and the Company, under which it agrees to acquire the number of Placing Shares allocated to it at the Issue Price on the terms and conditions set out in this Appendix and in accordance with the articles of association of the Company.

Except as required by law or regulation, no press release or other announcement will be made by Panmure Liberum or the Company using the name of any Placee (or its agent), in its capacity as Placee (or agent), other than with such Placee's prior written consent.

Irrespective of the time at which a Placee's allocation pursuant to the Placing is confirmed, settlement for all Placing Shares to be acquired pursuant to the Placing will be required to be made on the basis explained below under the paragraph entitled "Registration and Settlement".

All obligations under the Placing will be subject to fulfilment or (where applicable) waiver of, amongst other things, the conditions referred to below and to the Placing not being terminated on the basis referred to below.

By participating in the Placing, each Placee will agree that its rights and obligations in respect of the Placing will terminate only in the circumstances described below and will not be capable of rescission or termination by the Placee.

To the fullest extent permissible by law, neither Panmure Liberum nor any of its respective affiliates, agents, directors, officers or employees ("Representatives") shall have any liability to Placees (or to any other person whether acting on behalf of a Placee or otherwise under these terms and conditions). In particular, none of the Company, Panmure Liberum or any of its respective Representatives shall have any liability (including to the fullest extent permissible by law, any fiduciary duties) in respect of Panmure Liberum's conduct of the Placing. Each Placee acknowledges and agrees that the Company is responsible for the issue of the Placing Shares to the Placees and Panmure Liberum shall have no liability to the Placees for the failure of the Company to fulfil those obligations.

CONDITIONS OF THE PLACING

The Placing is conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.

Panmure Liberum 's obligations under the Placing Agreement in respect of the Placing Shares are conditional on, inter alia:

1.  the Company allotting, subject only to Admission, the Placing Shares in accordance with the Placing Agreement;

2.  the Company having complied with its obligations under the Placing Agreement;

3.  the passing of the Fundraising Resolutions (including those to facilitate the Share Capital Reorganisation) to be proposed at the annual general meeting of the Company to be held on or around 28 November 2024, or any adjournment thereof; and

4.  Admission becoming effective at or before 8.00 a.m. on 29 November 2024 (or such later date as may be agreed in writing between the Company and Panmure Liberum).

If (a) any of the conditions contained in the Placing Agreement in relation to the Placing Shares are not fulfilled or waived by Panmure Liberum by the respective time or date where specified (or such later time or date as the Company and Panmure Liberum may agree not being later than 3.00 p.m. on the "Final Date"; or (b) the Placing Agreement is terminated as described below, the Placing in relation to the Placing Shares will lapse and the Placee's rights and obligations hereunder in relation to the Placing Shares shall cease and terminate at such time and each Placee agrees that no claim can be made by the Placee in respect thereof.

Subject to certain exceptions, Panmure Liberum may, at its absolute discretion and upon such terms as it thinks fit, waive, or extend the period (up to the Final Date) for, compliance by the Company with the whole or any part of any of the Company's obligations in relation to the conditions in the Placing Agreement. Any such extension or waiver will not affect Placees' commitments as set out in this Announcement.

Neither Panmure Liberum nor the Company nor their respective affiliates shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision they may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition to the Placing nor for any decision they may make as to the satisfaction of any condition or in respect of the Placing generally and by participating in the Placing each Placee agrees that any such decision is within the absolute discretion of Panmure Liberum.

RIGHT TO TERMINATE UNDER THE PLACING AGREEMENT

Panmure Liberum is entitled, at any time before Admission, to terminate the Placing Agreement by giving notice to the Company in certain circumstances, including, inter alia:

1.  the Company has failed to comply with any of its obligations under the Placing Agreement which is material in the context of the Placing and/or Admission; or

2.  any of the conditions under the Placing Agreement shall have become incapable of fulfilment before the Final Date having not been waived under the Placing Agreement; or

3.  any of the warranties given by the Company to Panmure Liberum under the Placing Agreement not being true or accurate or being misleading when given or deemed given or repeated or deemed repeated (by reference to the facts and circumstances in each case then existing) in a respect which is material in the context of the Placing and/or Admission; or

4.  if, amongst other things, there is a material adverse change in the financial, political, economic or stock market conditions, which in the Panmure Liberum's reasonable opinion (acting in good faith) makes it impractical or inadvisable to proceed with the Placing; or

5.  if it comes to the notice of Panmure Liberum that any statement contained in the any public announcement made by the Company through a Regulatory Information Service was or has become untrue, incorrect or misleading in any respect which Panmure Liberum considers to be material or that any matter which such party considers to be material has arisen which would, if the Placing were made at that time, constitute a material omission therefrom.

Following Admission, the Placing Agreement is not capable of termination.

The rights and obligations of the Placees shall terminate only in the circumstances described in these terms and conditions and in the Placing Agreement and will not be subject to termination by the Placee or any prospective Placee at any time or in any circumstances. By participating in the Placing, Placees agree that the exercise by Panmure Liberum of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of Panmure Liberum and that it need not make any reference to Placees and that it shall have no liability to Placees whatsoever in connection with any such exercise or decision not to exercise.

Placees will have no rights against Panmure Liberum, the Company or any of their respective directors or employees under the Placing Agreement pursuant to the Contracts (Rights of Third Parties) Act 1999 (as amended).

NO PROSPECTUS

The Placing Shares are being offered to Relevant Persons only and will not be offered in such a way as to require a prospectus in the United Kingdom or elsewhere under the UK Prospectus Regulation or the Prospectus Regulation Rules Sourcebook published by the FCA. No offering document or prospectus has been or will be submitted to be approved by the FCA in relation to the Placing and Placees' commitments will be made solely on the basis of the information contained in this Announcement (including this Appendix) and certain business and financial information the Company is required to publish in accordance with the Companies Act 2006, the AIM Rules, UK MAR and the rules and practices of the FCA (collectively "Exchange Information").